Rosy cheeks, they say, are a sign of good health but in the case of rosacea, they are a hyper-reactive reality. Thus, in this patent application, Allergan has developed an α1-adrenoceptor that flushes out the truth.
Rosy cheeks, they say, are a sign of good health but in the case of rosacea, they are a hyper-reactive reality. Thus, in this patent application, Allergan has developed an α1-adrenoceptor that flushes out the truth.
α1-Adrenoceptor agonists to treat rosacea and skin erythema
U.S. Patent Application 20160082007
Publication date: March 24, 2016
Assignee: Allergan, Inc.
While various topical dermatological, cosmetic and pharmaceutical preparations and methods have been developed to treat rosacea, none has proven consistently effective in treating or preventing the vascular dilatation that characterizes erythema and flushing, which are hallmarks of the disease.
This invention describes a composition and method using α1-adrenergic receptor (α1-adrenoceptor) agonists incorporated into cosmetics or pharmacological and dermatological compositions. Upon topical application to the skin, the agonists address this vascular dilation.
Patent application accessed March 28, 2016.
